These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15142150)

  • 1. Antidiuresis: a new concept in managing female daytime urinary incontinence.
    Robinson D; Cardozo L; Akeson M; Hvistendahl G; Riis A; Norgaard JP
    BJU Int; 2004 May; 93(7):996-1000. PubMed ID: 15142150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome.
    Hashim H; Malmberg L; Graugaard-Jensen C; Abrams P
    Neurourol Urodyn; 2009; 28(1):40-6. PubMed ID: 18726947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of 400 microg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect.
    Hvistendahl GM; Riis A; Nørgaard JP; Djurhuus JC
    BJU Int; 2005 Apr; 95(6):804-9. PubMed ID: 15794787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis.
    Schulman SL; Stokes A; Salzman PM
    J Urol; 2001 Dec; 166(6):2427-31. PubMed ID: 11696804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis.
    Skoog SJ; Stokes A; Turner KL
    J Urol; 1997 Sep; 158(3 Pt 2):1035-40. PubMed ID: 9258137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study.
    van Kerrebroeck P; Rezapour M; Cortesse A; Thüroff J; Riis A; Nørgaard JP
    Eur Urol; 2007 Jul; 52(1):221-9. PubMed ID: 17280773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
    Steers W; Corcos J; Foote J; Kralidis G
    BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents.
    Stenberg A; Läckgren G
    Pediatrics; 1994 Dec; 94(6 Pt 1):841-6. PubMed ID: 7970999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
    Staskin DR; Te AE
    BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial.
    Yamaguchi O; Nishizawa O; Juul KV; Nørgaard JP
    BJU Int; 2013 Mar; 111(3):474-84. PubMed ID: 23046147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
    Martínez-García R; Abadías M; Arañó P; Perales L; Ruíz JL; Sust M; Conejero J;
    Eur Urol; 2009 Jul; 56(1):184-90. PubMed ID: 18485575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overnight testing of renal concentrating capacity in children using desmopressin tablets: sensitivity, repeatability and non-inferiority versus intranasal spray.
    Asa Rembratt ; Jens-Kristian Jensen ; Kjell Tullus ; Staffan Mårild ;
    Scand J Urol Nephrol; 2008; 42(3):274-7. PubMed ID: 17943639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial.
    Weiss JP; Zinner NR; Klein BM; Nørgaard JP
    Neurourol Urodyn; 2012 Apr; 31(4):441-7. PubMed ID: 22447415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis.
    Vande Walle JG; Bogaert GA; Mattsson S; Schurmans T; Hoebeke P; Deboe V; Norgaard JP;
    BJU Int; 2006 Mar; 97(3):603-9. PubMed ID: 16469035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.